请使用支持JavaScript的浏览器!
主营:抑制剂、激动剂、API
℡ 4000-520-616
℡ 4000-520-616
Medchemexpress/(R)-(+)-Etomoxir sodium salt(Synonyms: (+)-Etomoxir sodium salt)/HY-50202A/50mg
产品编号:HY-50202A-10mM*1mLinWater
市  场 价:¥1840.00
场      地:美国(厂家直采)
联系QQ:1570468124
电话号码:4000-520-616
邮      箱: info@ebiomall.com
美  元  价:$92.00
品      牌: MCE
公      司:Medchemexpress
公司分类:
Medchemexpress/(R)-(+)-Etomoxir sodium salt(Synonyms: (+)-Etomoxir sodium salt)/HY-50202A/50mg
商品介绍
(R)-(+)-EtomoxirsodiumsaltisR-formofEtomoxirsodiumsalt.Etomoxirisapotentinhibitorofcarnitinepalmitoyltransferase-I(CPT-1).
Description

(R)-(+)-EtomoxirsodiumsaltisR-formofEtomoxirsodiumsalt.Etomoxirisapotentinhibitorofcarnitinepalmitoyltransferase-I(CPT-1).

IC50&Target

CPT-1[1]

InVitro

(R)-(+)-EtomoxirsodiumsaltisR-formofEtomoxirsodiumsalt.EtomoxirbindsirreversIBLytothecatalyticsiteofCPT-1inhibitingitsactivity,butalsoupregulatesfattyacidoxidationenzymes.Etomoxirisdevelopedasaninhibitorofthemitochondrialcarnitinepalmitoyltransferase-1(CPT-1)locatedontheoutermitochondrialmembrane.Etomoxir,inthelivercanactasperoxisomalproliferator,increasingDNAsynthesisandlivergrowth.Thus,etomoxir,inadditionofbeingaCPT1inhibitorcouldbeconsideredasaPPARalphaagoNIST[1].EtomoxirisamemberoftheoxiranecarboxylicacidcarnitinepalmitoyltransferaseIinhibitorsandhasbeensuggestedasatherapeuticagentforthetreatmentofheartfailure.AcuteEtomoxirtreatmentirreversiblyinhibitstheactivityofcarnitinepalmitoyltransferaseI.Asaresult,fattyacidimportintothemitochondriaandβ-oxidationisreduced,whereascytosolicfattyacidaccumulatesandglucoseoxidationiselevated.Prolongedincubation(24h)withEtomoxirproducesdiverseeffectsontheexpressionofseveralmetabolicenzyme[2].

InVivo

(R)-(+)-EtomoxirsodiumsaltisR-formofEtomoxirsodiumsalt.Etomoxirisaninhibitoroffreefattyacid(FFA)oxidation-relatedkeyenzymeCPT1.P53interactsdirectlywithBax,whichisinhibitedbyEtomoxir,furtherconfirmingthedirectinteractionofP53andBax,andtheinvolvementofFAO-mediatedmitochondrialROSgenerationindb/dbmice[3].RatsareinjecteddailywithEtomoxir,aspecificCPT-Iinhibitor,for8daysat20mg/kgofbodymass.Etomoxir-treatedratsdisplaya44%reducedcardiacCPT-Iactivity.ThetreatmentofLewisratsfor8dayswith20mg/kgEtomoxirdoesnotalterbloodglucose,whichisinlinewithcomparableetomoxir-feedingstudies.Similarly,Etomoxirfeedingdoesnotaffectgeneralgrowthcharacteristicssuchasgaininbodymass,nordoesitaffecthindlimbmusclemass.However,heartmassandlivermassarebothsignificantlyincreasedby11%inEtomoxir-treatedrats[4].

References
  • [1].RuppH,etal.Theuseofpartialfattyacidoxidationinhibitorsformetabolictherapyofanginapectorisandheartfailure.Herz.2002Nov;27(7):621-36.

    [2].XuFY,etal.EtomoxirmediatesdifferentialmetabolicchannelingoffattyacidandglycerolprecursorsintocardiolipininH9c2cells.JLipidRes.2003Feb;44(2):415-23.

    [3].LiJ,etal.FFA-ROS-P53-mediatedmitochondrialapoptosiscontributestoreductionofosteoblastogenesisandbonemassintype2diabetesmellitus.SciRep.2015Jul31;5:12724.

    [4].LuikenJJ,etal.Etomoxir-inducedpartialcarnitinepalmitoyltransferase-I(CPT-I)inhibitioninvivodoesnotaltercardiaclong-chainfattyaciduptakeandoxidationrates.BiochemJ.2009Apr15;419(2):447-55.

CellAssay
[2]

EtomoxirisdissolvedinDMSOandstored,andthendilutedwithappropriatemediumbeforeuse[2].

RatheartH9c2myoblasticcellsareincubatedinDMEMcontaining10%fetalbovineserumuntilnearconfluence.Insomeexperiments,cellsarepreincubatedfor2hwithDMEM(serum-free)intheabsenceorpresenceof1-80μMEtomoxirandthenincubatedfor2hwith0.1mM[1-14C]oleicacid(10μCi/dish,bindstoBSAina1:1molarratio).Inotherexperiments,cellsarepreincubatedfor2hplusorminus40μMEtomoxirandthenincubatedfor2hwith0.1μMor0.1mM[1,3-3H]glycerol(10μCi/dish),0.1mM[1-14C]oleicacid(2μCi/dish,bindstoBSAina1:1molarratio),0.1mM[1-14C]palmiticacid(2μCi/dish,bindstoBSAina1:1molarratio),28μM[3H]ethanolamine(2μCi/dish),28μM[methyl-3H]choline(2μCi/dish),0.4mM[3H]serine(20μCi/dish),or40μMmyo-[3H]inositol(10μCi/dish).Themediumisremovedandthecellswashedtwicewithice-coldsalineandthenharvestedfromthedishwith2mLmethanol-water(1:1,v/v)forlipidextraction.AnaliquotofthehomogenateistakenforthedeterminationoftotaluptakeofrADIoactivityintocells.Phospholipidsarethenisolatedandradioactivityinthesedetermined[2].MCEhasnotindependentlyconfirmedtheaccuracyofthesemethods.Theyareforreferenceonly.

AnimalAdministration
[3][4]

Etomoxirisdissolvedin0.9%(w/v)NaCl(Rat)[4].

Mice[3]
80maleC57BLKS/Jlar-Leprdb/dbmiceand20wildtypelittermates(8week)areused.db/dbmicearerandomlydividedintofourgroups:db/dbgroup,Etomoxirgroup,MitoQgroup,andPFT-αgroup.IntheEtomoxirgroup,miceareintraperitoneallyinjectedwith1mg/kgEtomoxirtwiceeveryweek.IntheMitoQgroup,50μMMitoQisgiventothemiceinwater.Waterbottles,containingeitherMitoQ,arecoveredwithaluminumfoil,andallbottlesarerefilledevery3days.InthePFT-αgroup,miceareintraperitoneallyinjectedwith1mg/kgPFT-αtwiceeveryweek.WTmiceareadministratedwithvehicleinstead.Theexperimentalperiodis8weeks.Attheend,peripheralbloodsamplesandbonemarrowcellsareharvestedfortheassays.
Rat[4]
MaleLewisrats,weighing150-200g,areusedinthepresentstudy.Animalsarekeptona12h:12hlight/darkcycleandfedaPurinaChowdietandwateradlibitum.Theratsaredividedintotwogroups:(1)controland(2)Etomoxir.Etomoxir(20mg/kgofbodyweight)isdissolvedin0.9%(w/v)NaClandadministeredintraperitoneallyfor8days.Controlratsreceivesaline.Thelastinjectionisgiven24hbeforetheexperiment.Animalsareanaesthetizedwithanintraperitonealinjectionofanembutalandheparin(3:1)mixture.Subsequently,theheartisremovedforLCFAuptakestudiesandforanalysesoftransporterproteincontents.MCEhasnotindependentlyconfirmedtheaccuracyofthesemethods.Theyareforreferenceonly.

References
  • [1].RuppH,etal.Theuseofpartialfattyacidoxidationinhibitorsformetabolictherapyofanginapectorisandheartfailure.Herz.2002Nov;27(7):621-36.

    [2].XuFY,etal.EtomoxirmediatesdifferentialmetabolicchannelingoffattyacidandglycerolprecursorsintocardiolipininH9c2cells.JLipidRes.2003Feb;44(2):415-23.

    [3].LiJ,etal.FFA-ROS-P53-mediatedmitochondrialapoptosiscontributestoreductionofosteoblastogenesisandbonemassintype2diabetesmellitus.SciRep.2015Jul31;5:12724.

    [4].LuikenJJ,etal.Etomoxir-inducedpartialcarnitinepalmitoyltransferase-I(CPT-I)inhibitioninvivodoesnotaltercardiaclong-chainfattyaciduptakeandoxidationrates.BiochemJ.2009Apr15;419(2):447-55.

MolecularWeight

320.74

Formula

C₁₅H₁₈ClNaO₄

CASNo.

828934-41-4

Storage

4°C,storedundernitrogen

Shipping

RoomtemperatureincontinentalUS;mayvaryelsewhere

Solvent&Solubility

H2O:80mg/mL(Needwarming)

*"<1 mg/ml"="" means="" slightly="" soluble="" or="" insoluble.="" "≥"="" means="" soluble,="" but="" saturation="">

Purity:99.94%